miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究

doi:10.12092/j.issn.1009-2501.2019.05.010

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (5): 541-545.doi: 10.12092/j.issn.1009-2501.2019.05.010

miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究

郑中秋¹，谢伯剑¹，崔斌斌¹，柯抒晨²，林义²

¹浙江省台州医院，台州 317000，浙江；²温州医科大学附属第三医院妇产科，温州 325200，浙江

收稿日期:2018-12-24 修回日期:2019-04-22 出版日期:2019-05-26 发布日期:2019-05-28
作者简介:郑中秋，女，硕士，主治医师，研究方向：乳腺甲状腺外科。 Tel：13666857706 E-mail：zhengzq@enzemed.com
基金资助:
浙江省自然科学基金（TU20155645365）

miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells

ZHENG Zhongqiu ¹, XIE Bojian ¹, CUI Binbin ¹, KE Yichen¹, LIN Yi ²

¹ Taizhou Hospital of Zhejiang Province, Taizhou 317000, Zhejiang, China; ²Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, Zhejiang, China

Received:2018-12-24 Revised:2019-04-22 Online:2019-05-26 Published:2019-05-28

摘要/Abstract

摘要：

目的:探讨miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制。方法:随机选取2015年10月至2018年5月在本院进行手术切除的乳腺癌患者58例，取乳腺癌组织和癌旁组织提取细胞DNA，用荧光定量PCR的方法检测miR-106 b的表达量。购买乳腺癌MCF-7细胞系，构建促进miR-106 b表达的高表达组、抑制miR-106 b表达的低表达组细胞系。用不同浓度的顺铂处理，48 h后观察在体外和裸鼠皮下肿瘤的受抑制情况。荧光定量PCR法检测PTEN/PI3K/AKT信号通路相关基因的表达。结果:荧光定量PCR显示乳腺癌组织中miR-106 b的相对表达量高于癌旁组织（P<0.05）。在20、30和40 μmol/L浓度时，对照组和高表达组的相应浓度下的细胞抑制率均显著高于低表达组，对照组相应浓度下的细胞抑制率均显著高于低表达组（P<0.05）。在20、30和40 μmol/L浓度时，对照组和高表达组的相应浓度下的荧光强度均低于低表达组，且高表达组均显著低于对照组（P<0.05）。低表达组PTEN的相对表达量显著低于对照组，而高表达组PTEN的相对表达量显著高于对照组（P<0.05）。低表达组的PI3K和AKT的相对表达量显著高于对照组，高表达组的PI3K和AKT的相对表达量显著低于对照组（P<0.05）。结论:miR-106 b在乳腺癌中高表达，且表达量越高，乳腺癌细胞对顺铂的化疗敏感性越强。

关键词: miR-106 b, 乳腺癌, 顺铂, 化疗敏感性

Abstract:

AIM: To explore miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells. METHODS: Fifty-eight cases of breast cancer patients diagnosed and treated in our hospital from October 2015 to May 2015 were randomly selected. Breast cancer tissue and paracancer tissue were taken. Cellular DNA was extracted from breast cancer tissues and adjacent tissues, and the expression level of miR-106 b was detected by real-time PCR. MCF-7 cell lines of breast cancer were purchased to construct the high-expression group promoting the expression of mir-106 b and the low-expression group inhibiting the expression of miR-106 b. After 48 h treatment with cisplatin at different concentrations, the inhibition of tumors in vitro and subcutaneous in nude mice was observed. Fluorescence quantitative PCR was used to detect the expression of PTEN/PI3K/AKT signaling pathway related genes.RESULTS:Real-time PCR showed that the relative expression of miR-106 b in breast cancer tissues was higher than that in adjacent tissues (P<0.05). At 20, 30 and 40 μmol/L concentrations, the cell inhibition rates of the control group and the high expression group were significantly higher than those of the low expression group, and the cell inhibition rate of the control group was significantly higher than that of the low expression group (P<0.05). At the concentrations of 20, 30 and 40 μmol/L, the fluorescence intensity at the corresponding concentrations in the control group and the high expression group was lower than that in the low expression group, and the high expression group was significantly lower than the control group (P<0.05). The relative expression of PTEN in the low expression group was significantly lower than that in the control group, while the relative expression of PTEN in the high expression group was significantly higher than that in the control group (P<0.05). The relative expression levels of PI3K and AKT in the low expression group were significantly higher than those in the control group, and the relative expression levels of PI3K and AKT in the high expression group were significantly lower than those in the control group (P<0.05). CONCLUSION: miR-106 b is highly expressed in breast cancer, and the higher the expression, the more sensitive breast cancer cells are to cisplatin chemotherapy.

Key words: miR-106 b, breast cancer, cisplatin, chemotherapy sensitivity

中图分类号:

R965.2

郑中秋，谢伯剑，崔斌斌，柯抒晨，林义. miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 541-545.

ZHENG Zhongqiu, XIE Bojian, CUI Binbin, KE Yichen, LIN Yi. miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 541-545.

参考文献

［1］Li Q, Diao S, Li H, et al. Applying decision trees to establish risk rating model of breast cancer incidence based on non-genetic factors among Southwest China females［J］. Zhonghua Zhong Liu Za Zhi, 2018, 40(11): 872-877.
［2］Cassai A, Bonvicini D, Ruol M, et al. Erector spinae plane block combined with a novel technique for selective brachial plexus block in breast cancer surgery［J］. Korean J Anesthesiol, 2018, doi: 10.4097/kja.d.18.00266.
［3］Klaschik K, Hauke J, Neidhardt G, et al. The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk inBRCA1 mutation carriers ［J］. Int J Cancer, 2018, 144(7): 1761-1763.
［4］Santana Dos Santos E, Lallemand F, Burke L, et al. Non-coding variants in BRCA1 and BRCA2 genes: potential impact on breast and ovarian cancer predisposition［J］. Cancers (Basel), 2018, 10(11). pii: E453
［5］Wang L, Shang X, Feng Q. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis［J］. Cancer Biol Ther, 2019, 20(3): 261-271.
［6］Cui Y, Qin L, Tian D, et al. ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2［J］. Chemotherapy, 2018, 63(5): 262-271.
［7］Yen CS, Su ZR, Lee YP, et al. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma［J］. World J Gastroenterol, 2016, 22(22): 5183-5192.
［8］Weseslindtner L, Macheleidt I, Eischeid H, et al. Micro RNAs mir-106a, mir-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathy［J］. Liver Int, 2016, 36(3): 353-360.
［9］Han EC, Park JW, Kwon YH, et al. Do the oncological and surgical outcomes of young and older women differ in the treatment of colorectal cancer［J］? J Womens Health (Larchmt), 2019, 28(2): 258-267.
［10］Yan CX, Huang PT, Shentu WH, et al. Value of double contrast-enhanced ultrasound QontraXt three-dimensional pseudocolor quantitative analysis to therapeutic effect evaluation of preoperative neoadjuvant chemotherapyin advanced gastric cancer patients［J］. Zhonghua Zhong Liu Za Zhi, 2018, 40(11): 857-863.
［11］Atkinson CJ, Kawamata F, Liu C, et al. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer［J］. Mol Oncol, 2019, 13(4): 725-737.
［12］王彩玲, 王俊生. 培美曲塞联合顺铂治疗乳腺癌无症状脑转移的临床研究［J］. 中国合理用药探索, 2017, 14(12): 7-9.
［13］Yi D, Xu L, Wang R, et al. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1［J］. Cell Biol Int, 2019, 43(1): 12-21.
［14］Zhu W, Li J, Wu S, et al. Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer［J］. Pancreas, 2012, 41(7): 1029-1038.
［15］ Fahim Golestaneh A, Lecker LSM, Schlegel J, et al. Large scale in-vivo micro-RNA loss of function screen identified miR-29a, miR-100 and miR-155 as modulators of radioresistance and tumor-stroma communication［J］. Int J Cancer, 2019, 144(11): 2774-2781.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[9]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[10]	周欢, 徐铭, 李波, 刘春英, 王淳. PI3K/Akt/FOXO3a信号通路介导的保护性自噬参与肺腺癌获得性顺铂耐药表型重塑[J]. 中国临床药理学与治疗学, 2022, 27(9): 961-970.
[11]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[12]	王新丽, 许霞青, 方寒冰, 郭玉忠. 佛波酯增强顺铂的抗肿瘤活性及降低其肾毒性的作用研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 535-543.
[13]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[14]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[15]	崔华, 燕红霞, 尹梅. 下调lncRNA LINC00176对肺癌A549/DDP细胞顺铂耐药和自噬的影响[J]. 中国临床药理学与治疗学, 2021, 26(6): 616-623.

miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究

miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价